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The following Reply to the Editor refers to
an article and a corresponding letter to the
editor published in two previous issues of
the Journal: Cox JL, Ad N, Myers K,
Gharib M, Quijano RC. Tubular heart
valves: a new tissue prosthesis design—
preclinical evaluation of the 3F aortic bio-
prosthesis. J Thorac Cardiovasc Surg.
2005;130;520-7; and Biancucci B. Tubular
heart valves. J Thorac Cardiovasc Surg.
2006;131:1419.
Tubular heart valves
Reply to the Editor:
We are appreciative of the work that Mr
Biancucci performed while he was an em-
ployee of 3F Therapeutics, Inc, and we
welcome the opportunity to respond to his
letter.1 We regret that Mr Biancucci feels
slighted because he was not designated as
one of the authors on the article.2 It is our
practice to limit authorship for articles to
those who made significant and/or unique
contributions. There is a rather long list of
contributors who would have been consid-
ered for authorship before Mr Biancucci,
some of them extending back to when the
initial work on this valve began over 15
years ago.
Mr. Biancucci states: “The text gives
the impression that a laser micrometer was
used to measure aortic chamber compli-
ance during flow testing. Those measure-
ments were actually made on valveless
chambers in a separate test system before
flow testing.”
Unlike previous so-called “stentless”
tissue valves, there is no supporting struc-
ture whatsoever for the 3F Aortic Biopros-
thesis (3F Therapeutics, Inc, Lake Forest,
Calif). In fact, once implanted, the aortic
wall serves as the stent for this artificial
valve, much as it does for the native aortic
valve. Therefore, it was obvious that the in
vitro performance of this valve could be
affected by the material used to secure it
for testing. Thus, before initiating the in
vitro testing on this valve, we met with the
Food and Drug Administration (FDA) in
Washington, DC, to discuss proposals for
protocols on how to test this truly stentless
valve. The FDA Heart Valve Guidance, a
set of guidelines that includes stentless
valves, was followed precisely throughout
the testing procedure. The FDA’s guide-
lines called for the creation of two sets of
aortic compliance chambers, one set engi-
neered to 4% compliance and one set en-
gineered to 16% compliance. These precise
specifications were met by confirming
compliance of artificial aortic chambers us-
ing a laser micrometer, as stated clearly and
accurately in the article. The compliance of
these testing chambers was documented
without implanted valves, as prescribed by
the FDA, rather than during flow testing of
the bioprosthesis.
Mr Biancucci also objected to our de-
scription of the use of a corn starch solution
for a portion of the flow visualization stud-
ies that he characterized as “nonsensical.”
The corn starch scattering agent was used
for verification of the applicability of the
Bernoulli equation for Doppler flow stud-
ies, ultrasound requiring an acoustical scat-
terer, which perhaps we did not clarify
properly in the article. In the next para-
graph of the article, however, we clearly
described how “silver-coated glass parti-
cles of 40-m average size” were used
during laser flow visualization for particle
image velocimetry.
Mr Biancucci also took issue with our
use of the term “Hz” to describe the test
rate of the valves in the accelerated wear
tester. Our use of the term “Hz,” which is
commonly used to mean “cycles,” is tech-
nically incorrect. The rate should have
been stated as “700 to 900 cycles per
minute.”
Mr Biancucci implied that we mislead
readers in describing the wear testing of the
valve when we stated that we had per-
formed 2 tests each on 5 valve sizes for a
total of 10 wear tests. We actually per-
formed three times that number of tests on
the valve, so, in a sense, Mr Biancucci was
correct, though his implication was not.
The FDA requires 3 valves of the smallest
size, 3 valves of medium size, and 3 valves
of the largest size to be tested against one
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size 31-mm stented control valve. We ac-
tually tested 10 valves in each category of
small (19 mm), medium (25 mm) and large
(29 mm) sizes for a total of 30 wear tests.
Furthermore, to provide a more rigorous
trial for the valve, we tested it against the
SJM Toronto SPV (St Jude Medical, Inc, St
Paul, Minn), a stentless valve approved by
the FDA for commercial distribution in the
United States. We note that Mr Biancucci
did not challenge the accuracy of the data
that we reported for accelerated wear test-
ing in the article.
We agree with Mr Biancucci that the
paragraph titled “Visualization of Flow
Across the 3F Aortic Bioprosthesis” that
appears in the Results section of the paper
is technically incorrect in that it states that
we performed flow visualization studies in
valves other than the 19-mm valve size.
However, the unintentional and harmless
nature of this error is verified by the fact
that in that same paragraph we stated that
we used the smallest size valve (19 mm) in
the stiffest aortic testing chamber (4%
compliance) to illustrate the lack of turbu-
lence shown in Figures 4 and 5. In fact, the
FDA-sanctioned protocol, to which we
were meticulously adhering, called for the
testing of 19-mm valves only, because of
their predictably higher Reynolds numbers
and the scientifically acceptable practice of
extrapolating the lack of turbulence ob-
served in our small 19-mm valve to its
larger sizes without having to test the larger
sizes individually. Thus, the information
reported in the article relating to the lack of
turbulence associated with the 3F Aortic
Bioprosthesis is scientifically accurate and
conforms precisely to the FDA testing
protocol.
Again, rather than challenging the fun-
damental truth, accuracy, and/or interpreta-
tions of the finite element analysis studies,
Mr Biancucci chose to attack the technical
aspects of the manuscript. The original
studies were performed in 1991 to validate
or refute the concept of the tubular pros-
thesis and, as clearly shown in Figure 10,
confirmed that the greatest degree of stress
on a simple tube, subjected to the same
anatomic constraints as the native aortic
valve, occurs in the belly of the resultant
tubular “valve” and the least degree of
stress occurs where the commissural posts
of that tubular “valve” would be. The ab-
solute levels of stress on that hypothetical
tubular valve were far greater than the ab-
solute levels of stress that occur with the
actual 3F Aortic Bioprosthesis in its final
tubular design (Figure 6).
The relative stress scale shown beside
the valve leaflet in Figure 6 clearly shows
at the right side of the figure that the com-
missural region from the bottom to the top
is virtually stress free with only minor
stress along the leading edge of the leaflet
that disappears as it nears the region of the
commissural tab. It is possible that Mr Bi-
ancucci is referring to the minor stress on
the left side of the figure that appears to be
in the commissural attachment area but is
only so due to the orientation of the view.
Perhaps a quick review of the magnitude
and distribution of stress on currently avail-
able artificial tissue valves would enlighten
Mr Biancucci to the potential of the 3F
Aortic Bioprosthesis to extend the life of
artificial tissue valves.
Finally, in none of his comments, with
the possible exception of those directed at
the finite element studies, did Mr Biancucci
challenge the accuracy of the reported data
or of our interpretations of the data. Mr
Biancucci states in his closing paragraph
that his criticisms “are not intended to be
petty or esoteric.” There is little wonder
that he felt it necessary to add that dis-
claimer. Mr Biancucci may not be enam-
ored with the concept that underlies this
valve or with its tubular geometry, but the
objective observations described in our ar-
ticle would seem to trump his subjective
opinion. Furthermore, we question his
qualifications to lecture us, and by impli-
cation the editors and reviewers of the
Journal of Thoracic and Cardiovascular
Surgery, on the importance of producing
“intellectually and scientifically rigorous”
papers. One of the criteria of intellectual
honesty is to reserve authorship on scien-
tific papers to those contributors who have
earned it, a criterion that we are confident
was satisfied with the publication of this
article.
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Improved prosthesis–annulus
interaction and postoperative
hemodynamic performance of
new-generation aortic bioprosthesis
To the Editor:
We read with extreme interest the arti-
cle, “Small Aortic Annulus: The Hydro-
dynamic Performances of 5 Commercially
Available Tissue Valves,” published in the
May 2006 issue of the Journal.1 We would
like to congratulate Gerosa and coauthors
for the well-designed study, but we would
also add some brief comments. The authors
evaluated in vitro performances of 5 bio-
prosthesis designed for supra-annular im-
plantation and showed improved perfor-
mances of the Mitroflow valve compared
with the CE Perimount Magna (for cardiac
output  5 L/min). Inasmuch as the nom-
inal size is not uniform for different pros-
thesis, they compared the size of each type
fitting a 21-mm mounting ring (mimick-
ing a 21-mm aortic annulus). The concept
of supra-annular design is, however, dif-
ferent for the different prosthesis used in
the study. As we2 recently showed, the CE
Perimount Magna, the new generation of
CE Perimount characterized by a new sew-
ing cuff, allows the implantation of a big-
ger size prosthesis than does the standard
CE Perimount valve in almost 50% of pa-
tients. This is due to the improved interac-
tion between the new sewing cuff and the
aortic surgical annulus, which is not a flat
plane. This improved annulus-prosthesis in-
teraction could also explain the improved
in vivo performance of the CE Perimount
Magna when compared with the standard
CE Perimount valve of the same size, even
though the valve itself (housing and leaf-
lets) is not changed.
The supra-annular concept of the Mitro-
flow valve is different inasmuch as the
sewing ring is on a flat plane. The mount-
ing ring used in the study from Gerosa and
coauthors is also on a flat plane, and this
may have influenced the results of the study.
In vitro hemodynamic performances of the
CE Perimount Magna valve reported in this
study, in fact, do not reflect in vivo hemo-
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